Adaptimmune Therapeutics plc (NASDAQ:ADAP) CEO Adrian Rawcliffe Sells 2,707 Shares

Adaptimmune Therapeutics plc (NASDAQ:ADAP) CEO Adrian Rawcliffe sold 2,707 shares of the stock in a transaction on Tuesday, January 12th. The stock was sold at an average price of $6.15, for a total value of $16,648.05. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Adrian Rawcliffe also recently made the following trade(s):

• On Monday, January 4th, Adrian Rawcliffe sold 4,967 shares of Adaptimmune Therapeutics stock. The stock was sold at an average price of $5.33, for a total value of $26,474.11.

NASDAQ:ADAP opened at $5.82 on Thursday. The business’s 50-day moving average price is $5.02 and its two-hundred day moving average price is $7.03. Adaptimmune Therapeutics plc has a twelve month low of $2.00 and a twelve month high of $13.40. The stock has a market cap of $757.23 million, a P/E ratio of -5.88 and a beta of 2.40.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Tuesday, November 10th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. Adaptimmune Therapeutics had a negative return on equity of 44.94% and a negative net margin of 3,858.14%. The firm had revenue of $1.19 million for the quarter, compared to analysts’ expectations of $1.20 million. As a group, equities analysts expect that Adaptimmune Therapeutics plc will post -0.9 earnings per share for the current fiscal year.

A number of analysts recently issued reports on the company. BidaskClub raised Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 25th. SVB Leerink dropped their price objective on Adaptimmune Therapeutics from $10.00 to $6.00 and set a “market perform” rating on the stock in a report on Thursday, November 5th. ValuEngine cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 19th. Finally, Zacks Investment Research cut Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. Adaptimmune Therapeutics currently has an average rating of “Hold” and a consensus target price of $14.25.

Large investors have recently added to or reduced their stakes in the business. Chicago Partners Investment Group LLC purchased a new stake in shares of Adaptimmune Therapeutics in the 3rd quarter valued at about $56,000. Sowell Financial Services LLC raised its holdings in shares of Adaptimmune Therapeutics by 1,796.8% during the 4th quarter. Sowell Financial Services LLC now owns 11,286 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 10,691 shares in the last quarter. MAI Capital Management purchased a new position in shares of Adaptimmune Therapeutics during the 3rd quarter valued at about $92,000. Wrapmanager Inc. purchased a new position in shares of Adaptimmune Therapeutics during the 3rd quarter valued at about $125,000. Finally, Windsor Creek Advisors LLC purchased a new position in shares of Adaptimmune Therapeutics during the 3rd quarter valued at about $128,000. 99.79% of the stock is currently owned by hedge funds and other institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.

Featured Story: Penny Stocks, Risk and Reward Factors